Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Wednesday 06 May, 2009

Lipoxen PLC

Positive Phase I Clinical Dat

RNS Number : 7351R
Lipoxen PLC
06 May 2009

For immediate release
6 May 2009

Lipoxen plc

('Lipoxen' or 'the Company')

Positive Phase I Clinical Trial Results for ErepoXen®

~ A Novel Long-Acting EPO Product ~

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, is pleased to announce today that it has received positive Phase I clinical trial results for both efficacy and toxicity from the Company's long-acting erythropoietin (EPO) candidate, ErepoXen®.  ErepoXen® is being developed as a long-acting form of EPO, a product with annual sales of US$9bn, for the treatment of anaemia in cancer and renal disease patients. The study was conducted and funded by Lipoxen's partner and major shareholder, Serum Institute of India Limited (SIIL). 


      -    Data supports once monthly dosing (current EPO patients require up to three doses per week  at a cost
approximately $9k per patient per year in the UK)
      -    Significant red blood cell response which lasted between 14 and 20 days after dosing
      -    Sustained rise in haemoglobin levels for 28 days after dosing
      -    Drug well tolerated with no safety issues
      -    Phase II studies will commence in this quarter in India and a Phase I/II study in Canada in H2 09
      -    Product scheduled for market launch in Russia in 2011
      -    Discussions continuing with potential licensing partners 

This large Phase I trial was a randomised double-blind placebo-controlled single dose study and comprised 64 healthy adult males, 48 of whom received ErepoXen® while 16 received placebo. The subjects who received ErepoXen® were assigned to four dose cohorts: 0.5, 1.5, 3.0 and 4.5 micrograms/kg respectively. The trial was designed to assess the safety, pharmacokinetics and pharmacodynamics of ErepoXen®the polysialylated EPO, formulated using Lipoxen's proprietary PolyXen® technology. This technology is based on polysialic acid (PSA), (polymer occurring naturally in humans) which extends a protein's active life, is biodegradable, non-immunogenic and non-toxic, and which is also therefore expected to avoid the toxicity attributed to polyethylene glycol in PEGylated protein drug candidates. 

The pharmacodynamic data showed that ErepoXen® exerts a dose-dependent increase in reticulocyte (immature red blood cell) count. This increase was particularly prominent in the subjects receiving the two higher doses of ErepoXen®, with maximum reticulocyte count reached seven days after dosing. These subject's reticulocyte counts then took between 14 and 20 days to return to baseline values, suggesting that ErepoXen® could exert a long-acting effect on erythropoiesis (red blood cell production). This effect is comparable to that observed with CERA (Continuous Erythropoietin Receptor Activator), a Roche product, and is significantly longer than that observed with other shorter acting currently marketed EPOs.  Subjects receiving ErepoXen® also saw an increase in haemoglobin levels when compared to baseline and these effects lasted up to 28 days after dosing

Phase II studies with ErepoXen® are planned to commence in India this quarter and market launch is expected in Russia in 2011. A Phase I/II study in Canada will be conducted according to FDA guidelines and will also commence before the end of 2009. These clinical studies will be funded by SIIL, India's largest biotech company.

Commenting on this announcement, M. Scott Maguire, CEO of Lipoxen, said: 'We are very excited about this new clinical data which indicates that Lipoxen's ErepoXen® candidate has the potential to provide an improved and more convenient dosing regime for patients plus significant economic benefits for healthcare providers compared to current EPO products. The revenues for current EPOs (injected once to three times per week) totalled $9 billion in 2007 and thus we look forward to moving this product, which is funded by our partner, the Serum Institute of India, forward and into Phase II clinical trials next month. We have already begun discussions with potential commercial partners around this candidate and expect to sign a significant licensing deal in due course. Today's new data, together with the exciting flu vaccine data released last week, shows that Lipoxen's technologies are addressing pressing healthcare needs.' 

Adding to this announcement, the Phase I study's Principal investigator, Dr. Mikhail Ashraf*, Consultant Nephrologist and Senior Medical Tutor, Swansea University, said:  'I am pleased that the results we have announced today continue to confirm the excellent safety profile of polysialylated EPO. The overall data, particularly the mean reticulocyte and haemoglobin response, suggests that this novel EPO preparation would be suitable for once monthly administration.'

*Dr. Ashraf, an advisor to major multinational companies, has participated extensively in clinical trials of EPOs. He is an expert in anaemia management and has a special interest in erythropoiesis, having conducted phase-II and phase-III clinical trials for short and long acting ESAs.

- Ends -

For further information please contact:

Lipoxen plc

+44 (0)20 7691 3583 

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång 

Noble & Company

+44 (0) 20 7763 2200 

John Llewellyn-Lloyd / Sam Reynolds  

Buchanan Communications

+44 (0)20 7466 5000

Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye Dietrich, Catherine Breen

Notes for Editors

About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms:

1) PolyXen® - for extending the efficacy and half life of biologic drugs

2) ImuXen® - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA

Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its product candidates.  

Lipoxen has multiple drug and vaccine programmes in development. Two products are in clinical development, SuliXen®, a long acting insulin and ErepoXen®, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes candidates for Factor XIII and vaccines against HIV, influenza and malaria.  

The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities. Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited, Genentech, Amgen and Genzyme.  

Lipoxen plc, which was formed as a spin-out from The School of Pharmacy at the University of London, trades on the Alternative Investment Market (AIM) of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website:

This announcement includes 'forward-looking statements' which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words 'targets', 'believes', 'estimates', 'expects', 'aims', 'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Among the important factors that could cause the Company's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to The Company's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t